194 related articles for article (PubMed ID: 25545238)
1. Modeling of the pharmacokinetic/pharmacodynamic interaction between irbesartan and hydrochlorothiazide in normotensive subjects.
Hedaya MA; Helmy SA
Biopharm Drug Dispos; 2015 May; 36(4):216-31. PubMed ID: 25545238
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic interaction between irbesartan and hydrochlorothiazide in renal hypertensive dogs.
Huang XH; Qiu FR; Xie HT; Li J
J Cardiovasc Pharmacol; 2005 Dec; 46(6):863-9. PubMed ID: 16306814
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic properties and bioequivalence of two irbesartan/ hydrochlorothiazide fixed-dose combination tablets in healthy male Chinese volunteers.
Liu J; Wu L; Hu X; Wu G; Zheng Y; Zhou H; Zhai Y; Zhu M; ShenTu J
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):573-81. PubMed ID: 25828636
[TBL] [Abstract][Full Text] [Related]
4. PK-PD modeling of irbesartan in healthy Chinese adult volunteers under non-steady-state conditions.
Huang XH; Li J; Qiu FR; Xie HT; Huang JH; Li JC; Zheng QS
Eur J Drug Metab Pharmacokinet; 2006; 31(4):259-64. PubMed ID: 17315536
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic interactions of valsartan and hydrochlorothiazide: an open-label, randomized, 4-period crossover study in healthy Egyptian male volunteers.
Hedaya MA; Helmy SA
Clin Ther; 2013 Jun; 35(6):846-61. PubMed ID: 23795576
[TBL] [Abstract][Full Text] [Related]
6. Irbesartan and hydrochlorothiazide association in the treatment of hypertension.
Derosa G; Ferrari I; Cicero AF
Curr Vasc Pharmacol; 2009 Apr; 7(2):120-36. PubMed ID: 19355995
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension.
Neutel JM; Franklin SS; Bhaumik A; Lapuerta P; Oparil S
Clin Exp Hypertens; 2009 Oct; 31(7):572-84. PubMed ID: 19886855
[TBL] [Abstract][Full Text] [Related]
8. Influence of Single and Multi Dose Treatment of Glipizide on Pharmacokinetics and Pharmacodynamics of Irbesartan in Normal and Hypertensive Rats.
Anusha A; Narendar D; Krishna Murthy B; Goverdhan P
High Blood Press Cardiovasc Prev; 2017 Jun; 24(2):179-185. PubMed ID: 28386752
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics (PK/PD) of irbesartan in Beagle dogs after oral administration at two dose rates.
Carlucci L; Song KH; Yun HI; Park HJ; Seo KW; Giorgi M
Pol J Vet Sci; 2013; 16(3):555-61. PubMed ID: 24195292
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects.
Marino MR; Langenbacher K; Ford NF; Uderman HD
J Clin Pharmacol; 1998 Mar; 38(3):246-55. PubMed ID: 9549663
[TBL] [Abstract][Full Text] [Related]
11. Comparative bioavailability of two irbesartan/hydrochlorothiazide tablet formulations in Indonesian healthy subjects.
Sasongko L; Harahap Y; Prasaja B; Lusthom W; Setiawan EC; Meliala RS; Lipin
Arzneimittelforschung; 2010; 60(12):749-53. PubMed ID: 21265466
[TBL] [Abstract][Full Text] [Related]
12. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
Bobrie G;
Clin Ther; 2012 Aug; 34(8):1720-34.e3. PubMed ID: 22853847
[TBL] [Abstract][Full Text] [Related]
13. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
Weisser B; Gerwe M; Braun M; Funken C
Arzneimittelforschung; 2005; 55(9):505-13. PubMed ID: 16229114
[TBL] [Abstract][Full Text] [Related]
14. Physiologically Based Pharmacokinetic Modeling of Fimasartan, Amlodipine, and Hydrochlorothiazide for the Investigation of Drug-Drug Interaction Potentials.
Rhee SJ; Lee HA; Lee S; Kim E; Jeon I; Song IS; Yu KS
Pharm Res; 2018 Oct; 35(12):236. PubMed ID: 30324316
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension.
Huang QF; Sheng CS; Li Y; Ma GS; Dai QY; Wang JG;
Drugs R D; 2013 Jun; 13(2):109-17. PubMed ID: 23605903
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol.
Czendlik CH; Sioufi A; Preiswerk G; Howald H
Eur J Clin Pharmacol; 1997; 52(6):451-9. PubMed ID: 9342580
[TBL] [Abstract][Full Text] [Related]
17. [Irbesartan in clinical practice].
Malishevskiĭ MV
Kardiologiia; 2012; 52(11):66-74. PubMed ID: 23237398
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence studies for 2 different strengths of irbesartan/hydrochlorothiazide combination in healthy volunteers: 300/25 mg and 300/12.5 mg film-coated tablets.
Cánovas M; Cabré F; Polonio F
Drug Res (Stuttg); 2014 May; 64(5):257-62. PubMed ID: 24105103
[TBL] [Abstract][Full Text] [Related]
19. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ].
Schmieder RE; Krekler M
MMW Fortschr Med; 2005 Oct; 147 Suppl 3():97-101. PubMed ID: 16261944
[TBL] [Abstract][Full Text] [Related]
20. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.
Ruilope L
J Hypertens Suppl; 1997 Dec; 15(7):S15-20. PubMed ID: 9532516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
